Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -51.17% is 26% below its 5-year average of -40.52%, around the middle of its 5-year range (-69.31%–-19.52%).
As of the fiscal period ended Tuesday, June 30, 2026. 34.87% below its 12-month average of -37.94%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -51.17%.
RETURN ON EQUITY (ROE)
-51.17%
RETURN ON EQUITY (ROE) AVG TTM
-37.94%
RETURN ON EQUITY (ROE) AVG 3Y
-32.24%
RETURN ON EQUITY (ROE) AVG 5Y
-40.52%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-34.87%
CURRENT VS 3Y AVG
-58.73%
CURRENT VS 5Y AVG
-26.29%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 621 covered companies
CURRENT VS SECTOR MEDIAN
-27.29%
vs the sector median at left
Neurogene Inc.
Market Cap
$415.36M
Return on Equity (ROE)
-51.17%
TTM Avg
-37.94%
3Y Avg
-32.24%
5Y Avg
-40.52%
Market Cap
$419.57M
Return on Equity (ROE)
-69.06%
TTM Avg
36.89%
3Y Avg
36.89%
5Y Avg
36.89%
Market Cap
$411.32M
Return on Equity (ROE)
-37.05%
TTM Avg
-58.80%
3Y Avg
-40.96%
5Y Avg
-32.01%
Market Cap
$412.14M
Return on Equity (ROE)
-80.96%
TTM Avg
-47.93%
3Y Avg
-34.61%
5Y Avg
-20.56%
Market Cap
$409.27M
Return on Equity (ROE)
-28.18%
TTM Avg
-0.06%
3Y Avg
10.58%
5Y Avg
10.58%
Market Cap
$408.73M
Return on Equity (ROE)
-43.14%
TTM Avg
2.19%
3Y Avg
15.11%
5Y Avg
15.11%
Market Cap
$422.75M
Return on Equity (ROE)
-15.33%
TTM Avg
-56.08%
3Y Avg
-39.28%
5Y Avg
-33.86%
Market Cap
$397.84M
Return on Equity (ROE)
-65.99%
TTM Avg
-51.25%
3Y Avg
-81.12%
5Y Avg
-81.12%
Market Cap
$396.61M
Return on Equity (ROE)
-273.72%
TTM Avg
-138.09%
3Y Avg
-103.75%
5Y Avg
-71.29%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neurogene Inc. (NGNE) | $415.36M | -51.17% | -37.94% | -32.24% | -40.52% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $419.57M | -69.06% | 36.89% | 36.89% | 36.89% |
| Myriad Genetics, Inc. (MYGN)vs › | $411.32M | -37.05% | -58.80% | -40.96% | -32.01% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $412.14M | -80.96% | -47.93% | -34.61% | -20.56% |
| Shoulder Innovations, Inc. (SI)vs › | $409.27M | -28.18% | -0.06% | 10.58% | 10.58% |
| Carlsmed, Inc. (CARL)vs › | $408.73M | -43.14% | 2.19% | 15.11% | 15.11% |
| Prothena Corporation plc (PRTA)vs › | $422.75M | -15.33% | -56.08% | -39.28% | -33.86% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $397.84M | -65.99% | -51.25% | -81.12% | -81.12% |
| REGENXBIO Inc. (RGNX)vs › | $396.61M | -273.72% | -138.09% | -103.75% | -71.29% |
| Editas Medicine, Inc. (EDIT)vs › | $436.71M | -70.24% | -381.56% | -217.03% | -155.40% |
ROE
-51.2%
ROA
-45.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -51.17% |
| 2026-03-31 | -41.48% |
| 2025-12-31 | -34.11% |
| 2025-09-30 | -32.06% |
| 2025-06-30 | -30.88% |
| 2025-03-31 | -27.71% |
| 2024-12-31 | -24.21% |
| 2024-09-30 | -38.75% |
| 2024-06-30 | -30.71% |
| 2024-03-31 | -23.99% |
| 2023-12-31 | -19.52% |
| 2023-09-30 | -69.31% |
| 2023-03-31 | -66.31% |
| 2022-12-31 | -57.83% |
| 2022-09-30 | -55.61% |
| 2022-06-30 | -52.83% |
| 2022-03-31 | -46.96% |
| 2021-12-31 | -42.48% |
| 2021-09-30 | -37.56% |
| 2021-06-30 | -26.92% |
| 2021-03-31 | -22.12% |
| 2020-12-31 | -17.40% |
| 2020-09-30 | -14.34% |
| 2020-06-30 | -66.53% |
| 2020-03-31 | -55.34% |
| 2019-12-31 | -49.01% |
| 2019-09-30 | -99.03% |
| 2019-06-30 | -30.54% |
| 2019-03-31 | -26.80% |
| 2018-12-31 | -43.46% |
| 2018-09-30 | -56.00% |
| 2018-06-30 | -43.90% |
| 2018-03-31 | -65.82% |
| 2017-12-31 | -50.75% |
| 2017-09-30 | -39.58% |
| 2017-06-30 | -33.28% |
